Track market-moving stories before they get noisy

Brookstone Capital Management reduced its stake in shares of Lockheed Martin Corporation (NYSE:LMT – Free Report) by 4.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 20,082 shares of the aerospace company’s stock after selling 852 shares during the quarter. Brookstone Capital Management’s holdings in Lockheed Martin were worth $10,227,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of LMT. SeaCrest Wealth Management LLC boosted its stake in Lockheed Martin by 2.9% in the third quarter. SeaCrest Wealth Management LLC now owns 1,621 shares of the aerospace company’s stock valued at $825,000 after acquiring an additional 46 shares during the last quarter. NBT Bank N.A. bought a new stake in shares of Lockheed Martin during the 3rd quarter valued at $4,194,000. Isthmus Partners LLC raised its position in shares of Lockheed Martin by 0.6% during the 3rd quarter. Isthmus Partners LLC now owns 24,384 shares of the aerospace company’s stock valued at $12,418,000 after acquiring an additional 138 shares during the last quarter. Precedent Wealth Partners LLC lifted its stake in shares of Lockheed Martin by 19.3% in the 3rd quarter. Precedent Wealth Partners LLC now owns 5,673 shares of the aerospace company’s stock valued at $2,889,000 after purchasing an additional 919 shares during the period. Finally, Smith Chas P & Associates PA Cpas lifted its stake in shares of Lockheed Martin by 0.8% in the 3rd quarter. Smith Chas P & Associates PA Cpas now owns 88,708 shares of the aerospace company’s stock valued at $48,975,000 after purchasing an additional 668 shares during the period. Institutional investors and hedge funds own 74.19% of the company’s stock.

Lockheed Martin Stock Performance Shares of LMT opened at $604.87 on Friday. The company has a debt-to-equity ratio of 2.04, a quick ratio of 1.01 and a current ratio of 1.26. Lockheed Martin Corporation has a twelve month low of $437.25 and a twelve month high of $692.00. The firm’s 50 day moving average price is $538.52 and its two-hundred day moving average price is $542.30. The firm has a market cap of $139.60 billion, a P/E ratio of 21.49, a PEG ratio of 1.27 and a beta of 0.09.

Lockheed Martin (NYSE:LMT – Get Free Report) last announced its earnings results on Thursday, October 22nd. The aerospace company reported $7.97 earnings per share for the quarter, topping analysts’ consensus estimates of $7.52 by $0.45. The firm had revenue of $20.71 billion during the quarter, compared to analyst estimates of $20.48 billion. Lockheed Martin had a net margin of 8.23% and a return on equity of 83.41%. The company’s revenue for the quarter was up 11.3% compared to the same quarter last year. During the same period in the prior year, the business earned $6.95 EPS. On average, analysts forecast that Lockheed Martin Corporation will post 30.49 EPS for the current fiscal year. Lockheed Martin Increases Dividend The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 31st. Stockholders of record on Tuesday, December 1st will be paid a dividend of $3.60 per share. The ex-dividend date of this dividend is Tuesday, December 1st. This represents a $14.40 annualized dividend and a dividend yield of 2.4%. This is an increase from Lockheed Martin’s previous quarterly dividend of $3.45. Lockheed Martin’s dividend payout ratio (DPR) is 51.15%.

Wall Street Analysts Forecast Growth Several research analysts have recently issued reports on LMT shares. Wall Street Zen lowered Lockheed Martin from a “strong-buy” rating to a “buy” rating in a research report on Saturday, October 17th. Vertical Research upgraded Lockheed Martin from a “hold” rating to a “buy” rating and set a $600.00 price objective for the company in a report on Wednesday, October 14th. Morgan Stanley increased their target price on Lockheed Martin from $653.00 to $690.00 and gave the company an “equal weight” rating in a research note on Friday, July 24th. Jefferies Financial Group restated a “hold” rating on shares of Lockheed Martin in a report on Wednesday, September 2nd. Finally, Citigroup boosted their target price on Lockheed Martin from $691.00 to $706.00 and gave the stock a “buy” rating in a research report on Friday. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $632.33.

Get Our Latest Stock Report on Lockheed Martin

Lockheed Martin News Summary Here are the key news stories impacting Lockheed Martin this week:

Positive Sentiment: Q3 beat and raised outlook: Lockheed reported adjusted EPS of $7.97 versus the $7.52 consensus, while revenue rose 11.3% year over year to $20.71 billion. Management now expects 2026 sales of $80 billion-$82 billion and EPS of $30.35-$30.75. Lockheed Martin Reports Third Quarter 2026 Financial Results Positive Sentiment: Record backlog supports future revenue: Total backlog reached approximately $292 billion, up sharply from the prior quarter, with much of the increase coming from PAC-3 and THAAD missile-defense orders. Missiles and Fire Control sales grew 24% as production accelerated, strengthening visibility into long-term growth. Lockheed Martin’s Record $292 Billion Backlog Comes With a Delivery Test Positive Sentiment: Long-term F-35 commitment: The Pentagon and Lockheed announced an initial framework for producing 850 F-35 aircraft over 10 years. The agreement provides greater production visibility and could improve supply-chain efficiency, although Lockheed will invest about $7 billion in supporting projects. Pentagon, Lockheed announce agreement for 850 F-35 jets Positive Sentiment: Cash flow and shareholder returns: Lockheed raised its 2026 free-cash-flow outlook to roughly $7.8 billion-$8.0 billion and recently increased its quarterly dividend 4.4% to $3.60 per share. Lockheed Martin, Interactive Brokers, AEP Hike Dividends on Strong Growth Neutral Sentiment: Industry forecasts point to strong growth in defense electronics and land-based C4ISR, potentially expanding Lockheed Martin’s addressable market, but these reports are third-party projections rather than new company contracts. Negative Sentiment: Execution and funding risks remain: The backlog must be converted into deliveries and cash. F-35 deliveries fell year over year, and Lockheed said spending on the Lot 20 advance contract has exceeded currently authorized funding. Higher contract assets and supply-chain constraints could also delay cash collection or pressure margins. Lockheed is spending its own money before Washington signs off (Free Report)

Lockheed Martin Corporation is a global security and aerospace company headquartered in Bethesda, Maryland. Formed in 1995 through the merger of Lockheed Corporation and Martin Marietta, the company develops and produces advanced defense, aerospace, and technology systems for government and commercial customers.

Its principal business areas include Aeronautics, Missiles and Fire Control, Rotary and Mission Systems, and Space. Products and services include military aircraft such as the F-35 Lightning II, C-130 Hercules, and F-16 Fighting Falcon; missile-defense and precision-strike systems; helicopters and naval systems; command, control, communications, and intelligence technologies; satellites; space exploration systems; and other classified space and defense programs.

Lockheed Martin serves the U.S.

Recommended Stories Five stocks we like better than Lockheed Martin Spotify Soars After Earnings as the Company Touts AI Benefits and Moderating Costs Lockheed Martin’s Record $292 Billion Backlog Comes With a Delivery Test Palantir’s Next Big Test Isn’t a Partnership—It’s the Numbers Kinder Morgan’s $4.7 Billion Pipeline Bet Could Be Bigger Than Its Earnings Beat Want to see what other hedge funds are holding LMT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lockheed Martin Corporation (NYSE:LMT – Free Report).

Receive News & Ratings for Lockheed Martin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lockheed Martin and related companies with MarketBeat.com's FREE daily email newsletter.

Atlatl Advisers LLC decreased its holdings in shares of Lam Research Corporation (NASDAQ:LRCX – Free Report) by 89.8% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,646 shares of the semiconductor company’s stock after selling 14,564 shares during the quarter. Atlatl Advisers LLC’s holdings in Lam Research were worth $541,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. World Equity Group Inc. increased its holdings in shares of Lam Research by 0.5% during the 2nd quarter. World Equity Group Inc. now owns 5,576 shares of the semiconductor company’s stock valued at $2,416,000 after acquiring an additional 29 shares during the last quarter. Vann Equity Management LLC lifted its position in Lam Research by 1.1% during the 3rd quarter. Vann Equity Management LLC now owns 2,873 shares of the semiconductor company’s stock worth $944,000 after acquiring an additional 31 shares during the last quarter. Tenzing Financial LLC boosted its holdings in Lam Research by 3.5% during the second quarter. Tenzing Financial LLC now owns 1,018 shares of the semiconductor company’s stock valued at $441,000 after acquiring an additional 34 shares during the period. Advus Financial Partners LLC boosted its holdings in Lam Research by 1.0% during the second quarter. Advus Financial Partners LLC now owns 3,578 shares of the semiconductor company’s stock valued at $1,550,000 after acquiring an additional 34 shares during the period. Finally, Paragon Private Wealth Management LLC grew its position in shares of Lam Research by 1.3% in the second quarter. Paragon Private Wealth Management LLC now owns 2,719 shares of the semiconductor company’s stock valued at $1,178,000 after purchasing an additional 35 shares during the last quarter. 84.61% of the stock is currently owned by institutional investors.

Insiders Place Their Bets In related news, insider Ava Harter sold 5,000 shares of the firm’s stock in a transaction on Monday, August 31st. The stock was sold at an average price of $302.46, for a total value of $1,512,300.00. Following the completion of the transaction, the insider directly owned 42,462 shares of the company’s stock, valued at $12,843,056.52. This trade represents a 10.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bethany Mayer sold 9,557 shares of Lam Research stock in a transaction on Wednesday, September 9th. The stock was sold at an average price of $314.74, for a total transaction of $3,007,970.18. Following the sale, the director owned 20,995 shares in the company, valued at $6,607,966.30. This represents a 31.28% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 0.31% of the company’s stock.

Lam Research Trading Down 0.0% Shares of LRCX opened at $230.10 on Friday. Lam Research Corporation has a 12-month low of $135.50 and a 12-month high of $438.50. The company has a quick ratio of 1.91, a current ratio of 2.48 and a debt-to-equity ratio of 0.27. The firm has a market capitalization of $287.95 billion, a price-to-earnings ratio of 34.29, a P/E/G ratio of 0.83 and a beta of 1.85. The stock’s 50-day moving average price is $301.90 and its 200 day moving average price is $309.32. Lam Research (NASDAQ:LRCX – Get Free Report) last posted its quarterly earnings results on Wednesday, October 21st. The semiconductor company reported $2.20 EPS for the quarter, beating the consensus estimate of $2.18 by $0.02. Lam Research had a return on equity of 72.15% and a net margin of 32.34%. The firm had revenue of $8.22 billion during the quarter, compared to analysts’ expectations of $8.14 billion. During the same quarter in the prior year, the firm posted $1.26 EPS. The company’s revenue for the quarter was up 54.4% on a year-over-year basis. As a group, research analysts predict that Lam Research Corporation will post 9.48 earnings per share for the current year.

Lam Research Increases Dividend The company also recently announced a quarterly dividend, which was paid on Wednesday, October 14th. Investors of record on Wednesday, September 23rd were paid a $0.33 dividend. The ex-dividend date was Wednesday, September 23rd. This is a positive change from Lam Research’s previous quarterly dividend of $0.26. This represents a $1.32 dividend on an annualized basis and a dividend yield of 0.6%. Lam Research’s dividend payout ratio is currently 22.92%.

Analysts Set New Price Targets A number of equities analysts have recently commented on LRCX shares. Berenberg Bank set a $420.00 price objective on Lam Research in a research note on Wednesday, September 9th. Fundamental Research set a $390.00 target price on Lam Research in a research note on Thursday, October 1st. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $375.00 price target on shares of Lam Research in a research report on Monday. Jefferies Financial Group set a $335.00 price target on Lam Research and gave the stock a “buy” rating in a report on Thursday, July 30th. Finally, HSBC reissued a “hold” rating and issued a $333.00 price objective on shares of Lam Research in a research report on Monday, July 27th. One research analyst has rated the stock with a Strong Buy rating, twenty-six have given a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat.com, Lam Research has an average rating of “Moderate Buy” and a consensus price target of $354.55.

Check Out Our Latest Report on Lam Research

Trending Headlines about Lam Research Here are the key news stories impacting Lam Research this week:

Positive Sentiment: Record results and strong profitability: Fiscal first-quarter revenue rose 54.4% year over year to $8.22 billion, exceeding estimates, while adjusted EPS of $2.20 also beat forecasts. Operating margin topped 40% for the first time, supported by strong systems sales, memory demand and record foundry revenue. Lam Research Q1 Earnings Beat on Systems Sales and Margin Gains Positive Sentiment: Long-term AI and memory demand remains supportive: Lam expects wafer-fabrication-equipment spending to exceed $200 billion in 2027, driven by AI infrastructure, memory upgrades and advanced manufacturing. Customer Support revenue is expected to grow more than 30%, while Aether dry-resist revenue is projected to reach $2.5 billion cumulatively. LRCX Q1 Earnings Call Highlights Positive Sentiment: Some analysts remain bullish: Mizuho reiterated an Outperform rating and recommended buying the pullback, while Bank of America maintained a Buy rating. Erste Group also modestly increased its FY2027 and FY2028 EPS estimates. Mizuho recommends buying the pullback Neutral Sentiment: Guidance was broadly in line but leaves limited room for disappointment: Fiscal second-quarter revenue guidance of $8.2 billion-$9.0 billion and EPS guidance of $2.18-$2.48 bracket consensus estimates of $8.5 billion and $2.30, respectively. Mizuho trimmed its price target to $360 from $365, signaling continued upside but greater near-term caution. Negative Sentiment: Supply bottlenecks are limiting shipments: Component shortages and cleanroom capacity constraints could restrict equipment deliveries through 2027, preventing Lam from fully converting strong demand into revenue. Lam Research says supply bottlenecks are holding back revenue Negative Sentiment: China exposure and sector pressure are weighing on sentiment: China’s revenue contribution is expected to decline substantially from 35% in the September quarter. Citi warned of additional downside for Lam and peers, while a broad AI-chip sell-off amplified concerns about valuations and spending. Lam Research Profile (Free Report)

Lam Research Corporation (NASDAQ:LRCX) is a semiconductor equipment company that develops and manufactures systems used to fabricate integrated circuits. Its technologies support key stages of wafer processing, helping semiconductor manufacturers create the increasingly complex structures found in memory, logic and other types of chips.

The company’s product portfolio includes etch systems, which selectively remove materials from wafers; deposition systems, which apply thin films; and cleaning solutions used to remove contaminants and residue during manufacturing.

Featured Articles Five stocks we like better than Lam Research Spotify Soars After Earnings as the Company Touts AI Benefits and Moderating Costs Lockheed Martin’s Record $292 Billion Backlog Comes With a Delivery Test Palantir’s Next Big Test Isn’t a Partnership—It’s the Numbers Kinder Morgan’s $4.7 Billion Pipeline Bet Could Be Bigger Than Its Earnings Beat

Receive News & Ratings for Lam Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lam Research and related companies with MarketBeat.com's FREE daily email newsletter.

Investors questioning the returns on artificial intelligence (AI) spending should consider securing exposure to another sector: US homebuilders.

Housing stocks charged higher on Thursday as Treasury yields declined, offering a glimpse of how they stand to benefit from a rotation out of technology due to AI bubble concerns.

D.R. Horton, Lennar, and PulteGroup all posted “strong intraday gains” as investors reassessed an industry battered by expensive financing.

The attraction goes beyond a rotation: sustained mortgage-rate relief could improve affordability for buyers and reduce the financial concessions builders need to close sales.

Housing offers a concrete way to invest in falling borrowing costs. Freddie Mac reported Thursday that the average 30-year fixed mortgage rate slipped to 7.32% from 7.40% a week earlier.

That remains rather expensive, but the direction matters for households whose purchasing decisions depend heavily on monthly payments.

For homebuilders, a sustained decline could deliver two benefits – more qualified buyers and less pressure to subsidize financing.

Mortgage-rate buydowns help move inventory, but they consume money as well that could otherwise support profitability.

The opportunity therefore extends beyond stronger sales volumes.

Homebuilders could eventually retain more profit on each closing as affordability improves.

However, one weekly decline doesn’t establish a recovery, and mortgage rates need not follow Fed policy moves precisely.

US homebuilder stocks offer material exposure to household formation, employment, and housing affordability, giving investors a different set of earnings drivers from the companies financing the AI infrastructure boom.

The sector’s current difficulties also explain its recovery potential.

October’s NAHB/Wells Fargo Housing Market Index fell to 29, while 43% of builders reported cutting prices and 65% offered sales incentives.

Those figures reveal notable operating pressure that easing financing conditions could gradually relieve.

Still, investors should distinguish a rotation opportunity from a dependable hedge. An AI sell-off accompanied by widespread job losses could undermine housing demand even as bond yields fall.

The strongest backdrop would be moderating inflation and stable employment: enough economic resilience to support purchases, alongside lower borrowing costs.

Selective exposure makes more sense than assuming every housing-related business will benefit equally.

D.R. Horton NYSE:DHI stands out because its national scale and broad product offering provide multiple avenues to capture improving demand.

America’s largest builder by volume operates across 126 markets in 36 states, reducing dependence on any single local housing economy.

Its mortgage-financing business also gives it tools to address buyers’ affordability constraints.

Its latest reported quarter demonstrates resilience: fiscal Q3 closings increased 4% to 23,983 homes, generating $9.2 billion in consolidated revenue and $904.9 million in net income.

Nevertheless, cancellations increased to 20% from 17% a year earlier, underscoring continued buyer hesitation.

That combination makes Horton a credible recovery candidate with an established earnings base.

Its October 29 results will provide the next test: investors should watch incentives, cancellations, and margins before treating Thursday’s rally as evidence of a lasting turnaround.

Iridium Communications (IRDM +1.39%) announced its Q3 2026 earnings Tuesday morning, Oct. 20. Shares of the satellite communications company are basically flat since -- they cost $44.18 Monday evening before earnings, and they cost $44.25 at Wednesday's close. Rocket Lab (RKLB +2.69%) stock, on the other hand, is up a healthy 4.5% since Iridium reported its earnings.

Why is that?

It's because it doesn't really matter much anymore -- or soon won't -- how well Iridium does. Rocket Lab is buying Iridium, you see (in an $8 billion deal). And for this reason, Iridium's good news is actually really Rocket Lab's good news.

Image source: Getty Images.

How Iridium beat earnings in Q3
Heading into its report Tuesday, Wall Street analysts had Iridium pegged for a $ 0.34-per-share profit on $236.3 million in sales. Iridium crushed both numbers, reporting $0.98 per share in profit (nearly three times what the Street predicted) on sales of $245.7 million.

How did Iridium do that? Largely by making an acquisition of its own, of space-based air traffic surveillance company Aireon.

Iridium reacquired Aireon in July, and Iridium management credits this acquisition with much of its 8% year-over-year revenue increase. Gains "related to the acquisition of Aireon" likewise accounted for Iridium's earnings coming in triple what Wall Street expected. Perhaps more important for Rocket Lab investors, Iridium noted that bringing Aireon in-house gave Iridium control over "the world's only space-based Automatic Dependent Surveillance-Broadcast (ADS-B) air traffic surveillance system."

And when Rocket Lab's own acquisition of Iridium takes effect mid-next-year, that will mean Rocket Lab owns the world's only space-based air traffic surveillance system, making it a key part of Rocket Lab's plan to expand into satellite-based Internet of Things (IoT), direct-to-cell communications, and "position, navigation, and timing" (PNT) markets.

IRDM Iridium Communications$44.40+$0.61 (+1.39%)

NASDAQ · As of 4:00 PM ET 10/23/26

Speaking of which, now that Iridium shareholders have voted to approve the merger -- and now that Iridium has reported its latest financials -- it's worth taking a second look at how this merger will affect Rocket Lab once it absorbs Iridium (and Aireon) next year.

As I've already pointed out, analysts are optimistic about Iridium. Forecasts compiled by S&P Global Market Intelligence indicate Iridium should earn more than $210 million next year, up 35.5% year over year, even if revenue doesn't grow much at all. Free cash flow is expected to grow more slowly, but still to rise a very respectable 28% to $379 million.

Assuming the analysts are doing their math right, that should be more than enough to cover Rocket Lab's expected $74 million loss next year, and make whole its $83 million in negative free cash flow as well. Thanks entirely to its prescient decision to buy Iridium, Rocket Lab should end up both profitable and free cash flow positive in 2027.

Indeed, Iridium might end up making even more money for Rocket Lab than analysts currently expect.

Consider: Current analyst estimates have Iridium earning $155 million this year, but according to the just-released Q3 earnings results, Iridium has already earned more than $138 million in just the first three quarters of 2026.

With 75% of the year over, Iridium is already 89% of the way to hitting the analysts' target for this year! And if Iridium is this far ahead of the game already in 2026, and growing faster than expected, it stands to reason that 2027's results might similarly come in stronger than what analysts have forecast.

RKLB Rocket Lab$52.60+$1.38 (+2.69%)

NASDAQ · As of 4:00 PM ET 10/23/26

What it means for Rocket Lab investors
At least, that's what Rocket Lab investors will be hoping. Back-of-the-napkin, it's looking now like a combined Rocket Lab-plus-Iridium might generate $300 million or so in positive free cash flow next year, which on Rocket Lab's current $45 billion market capitalization works out to a 150x forward price-to-free cash flow ratio on the stock.

That's... not exactly cheap. For Rocket Lab to be a buy at its current price, it had better hope Iridium performs even better in 2027 than it's already performing in 2026.

While many will tell you the biggest bottleneck in AI is the chip supply, I actually believe it's electricity. Because of this, Bloom Energy (BE -11.24%) will be the biggest winner of the AI power crunch for one reason in particular: The company's speed to power is top-notch.

AI hyperscalers and their data centers cannot wait years for utility hookups. Bloom's solid oxide fuel cells help businesses avoid this wait. The company's systems can bring a data center online in about three months and don't require grid connectivity. This is a massive advantage, and customers are coming on board at record scale.

$193.30-$24.47 (-11.24%)

NYSE · As of 4:00 PM ET 10/23/26

The demand behind Bloom is quickly converting to revenue, as the company crossed $1 billion in the second quarter, a 166% year-over-year increase. Bloom's balance sheet is improving rapidly, with the company boasting about $2.7 billion in cash.

Management raised its full-year guidance to reflect a substantial increase in revenue, with a range of $3.9 billion to $4.2 billion. That's just about double what the company did in 2025.

Image source: The Motley Fool.

All this momentum means the stock isn't cheap. Shares have skyrocketed more than 150% year to date. The stock is trading at a whopping 357 times trailing earnings. For long-term investors, the premium is justified by the ever-improving balance sheet and incessant demand for fast power. We're still early on in the AI and data center days. Bloom's systems will be needed for years to come.

Catie Hogan has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Bloom Energy. The Motley Fool has a disclosure policy.

Apple (AAPL -0.14%) is one of the greatest businesses we've ever seen. That's indicated by its shares soaring 1,080% in the past 10 years (as of Oct. 21) and its market capitalization of $5 trillion. It is perhaps second to none when it comes to hardware and software design, supporting its position as a powerful consumer brand with loyal customers.

The Cupertino success story is one of the most profitable companies on the face of the planet. Here's why it might be worth $295 a share right now, which represents a 14% discount to the current stock price of $344.

Image source: The Motley Fool.

Pricing power is key to Apple's profitability During the most recent fiscal quarter (third-quarter 2026 ended June 27), the company reported $29.8 billion in net income. That's truly a massive figure. Investors must understand why Apple has built such an extremely lucrative business model.

Credit goes to constant pricing power. Apple's popular devices aren't cheap. But historically, customers have not only shown a willingness to pay up for these products, they tend to upgrade when new iterations come out.

The services segment deserves some attention, too. Last quarter, it represented 28% of the company's revenue, a share that has trended higher over time. Its gross margin of 76% is much better than the 40% that products generate.

Besides the fat margins, what's equally impressive is the durability of the profits. Unlike many of today's artificial intelligence winners, which could end up being one-hit wonders, Apple has been raking it in for a long time. A decade ago, in fiscal 2016, it reported a net margin of 21%. In recent history, this has helped the business produce significant free cash flow that flows to share buybacks and dividends.

AAPL Apple$347.73-$0.50 (-0.14%)

NASDAQ · As of 4:00 PM ET 10/23/26

Shares are currently overvalued The "Magnificent Seven" stock currently trades at 35 times forward earnings estimates. That's certainly an expensive valuation. The S&P 500 index trades at a forward price-to-earnings (P/E) ratio of 19.3, giving Apple a sizable premium of 81%. Value investors might turn away from this business.

There are two sides to the story here. I think it's very easy to argue, based on the forward P/E multiple, that Apple is overvalued right now. The challenge is figuring out what the right multiple should be. Because this is such a high-quality company, maybe a forward P/E ratio of 30 is correct. This implies that the stock is worth $295 right now.

On the other hand, Apple bulls won't hesitate to say that the shares are deserving of a high price tag. This business has certainly earned the market's respect, and there's nothing that says it can't keep producing winning returns in the future.

The S&P 500 is full of quality dividend stocks. But is Pfizer (PFE -1.28%) one of them? On the one hand, the drugmaker has one of the highest yields in the index. However, some would point out that Pfizer has faced significant challenges and still has important ones on the horizon. Still, in my view, Pfizer is an attractive income stock to buy and hold. Here's why the dividend is safer than it appears at first.

Recent financial results have exceeded estimates Reduced demand for coronavirus products has affected Pfizer's financial results in recent years. In the second quarter, the company's COVID-19 vaccine, Comirnaty, reported $261 million in sales, down 32% year over year. Pfizer's coronavirus medicine, Paxlovid, performed even worse. The drug posted only $21 million in revenue, down 95% compared to the year-ago period.

Image source: The Motley Fool.

Despite that, Pfizer's total revenue climbed by 3% year over year to about $15 billion. As management has pointed out, the company has exceeded revenue expectations in nine out of the past 10 quarters, and it beat earnings estimates in all 10 of them. True, Pfizer is racing toward important patent cliffs, including that of Eliquis, an anticoagulant, its best-selling medicine.

Eliquis will lose its U.S. patent by the end of the decade. Two other drugs facing patent-exclusivity losses are Ibrance and Xtandi, both of which are cancer drugs. Still, Pfizer's newer and acquired products will help the company overcome this challenge. CEO Albert Bourla noted that these products generate $13 billion in annualized sales and are growing 20% year over year.

Suppose these medicines grow at a compound rate of 15% through the next four years. Their annualized revenue would get to $22.7 billion by 2030. As of the first half of the year, Ibrance, Xtandi, and Eliquis have combined annualized sales of $15.27 billion. That will certainly grow meaningfully before they hit their patent cliffs, and it's not as if their revenue will immediately drop to zero following their loss of patent exclusivity. Does that mean the new (and acquired) products will more than offset the loss-of-exclusivity products? Probably not.

But Pfizer is preparing for this challenge better than some investors realize. We can also look at the work it has done to increase profits. The company eliminated $7.2 billion from its cost base in the past three years. That's a meaningful amount, and future cost-cutting measures could also positively impact the drugmaker's results and help it navigate the difficult period it is entering.

PFE Pfizer$30.03-$0.39 (-1.28%)

NYSE · As of 4:00 PM ET 10/23/26

Pipeline progress is key Is Pfizer's dividend program -- which boasts a juicy 5.8% forward yield -- in trouble as the company faces several patent cliffs? Probably not. Here are two reasons why. First, Pfizer hasn't reduced its dividend in recent years, despite the challenges it has faced. The past isn't a guarantee of the future, but recent history suggests that management prioritizes returning capital to shareholders through dividends.

In the past five years, the company has increased its payouts by 10.26%. That's not extraordinary, but given the challenges it has faced, it's still fairly impressive. Second, beyond recent brand-new approvals, Pfizer boasts a deep pipeline that should help the company significantly expand its lineup of approved products over the next few years.

This is where even stronger growth could come from, especially since Pfizer boasts several highly promising candidates. For instance, the company's investigational long-acting GLP-1 weight-loss medicine, berobenatide, could eventually generate well over $1 billion in sales, given its monthly dosing schedule, strong tolerability, and the predicted rapid growth of the anti-obesity market.

That's just one of the more notable products in Pfizer's pipeline. Of course, the company could face clinical setbacks. But Pfizer's pipeline is deep: It boasts some 16 brand-new products in Phase 3 studies. That's not including earlier-stage programs. Even a modest Phase 3 success rate of 50% -- which is well in line with the industry average -- will lead to a good number of brand-new products over the next few years. These are all good reasons why Pfizer's outlook appears fairly strong, and the dividend looks safe, despite recent headwinds.

Sofetabart mipitecan (Sofe-M) in combination with bevacizumab demonstrated a 79% confirmed objective response rate and 100% disease control rate, with similar activity observed across FRα expression levels

Clinical activity with Sofe-M was maintained even in patients with prior PARP inhibitor exposure, patients who typically experience poor outcomes with platinum-based chemotherapy

Sofe-M is currently being studied in both platinum-sensitive and platinum-resistant ovarian cancer in multiple Phase 3 studies as part of the FRAmework-01 master protocol

, /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new Phase 1 data showing that its investigational folate receptor alpha (FRα) antibody-drug conjugate (ADC) sofetabart mipitecan (Sofe-M) plus bevacizumab achieved a confirmed objective response rate (cORR) of 79% and a disease control rate (DCR) of 100% in patients with platinum-sensitive ovarian cancer (PSOC). A cORR of 79% or higher was seen in both poly (ADP-ribose) polymerase inhibitor (PARPi)-treated and PARPi-naïve patients. These data will be shared in an oral presentation at the European Society for Medical Oncology (ESMO) Annual Congress in Madrid, Spain.

FRα is expressed in almost all ovarian cancers, at much higher levels than in healthy tissue, making it a target that can help direct treatment to tumor cells. Sofe-M is an FRα-targeting ADC composed of an Fc-silent, FRα-specific humanized monoclonal antibody linked to exatecan, a topoisomerase I inhibitor, via a proprietary cleavable polysarcosine linker. The antibody is designed to bind FRα on the surface of tumor cells, delivering exatecan directly into the tumor cell to disrupt DNA replication.

Jacob Van Naarden, Executive Vice President and President of Lilly Oncology: "The standard of care for platinum-sensitive ovarian cancer has remained unchanged for a decade and demands new treatment options. Results for Sofe-M show a promising efficacy and tolerability profile across both platinum-resistant and platinum-sensitive ovarian cancer, regardless of FRα expression levels or prior treatment. These data give us confidence as we continue to study Sofe-M in our Phase 3 FRAmework-01 program to bring this potential new medicine to the women who need it."

The Phase 1 study is evaluating Sofe-M plus bevacizumab in patients with advanced solid tumors, including a cohort of 33 women with PSOC who received Sofe-M (4 mg/kg) plus bevacizumab (15 mg/kg). Patients received a median of three prior systemic regimens (range 1–6), including prior PARPi (67%) and prior bevacizumab (70%). As of the July 6, 2026, data cutoff, the cORR among the 29 patients with measurable disease was 79.3% (23/29; 6 complete responses [CR, 20.7%] and 17 partial responses [PR, 58.6%]), and DCR was 100%. Responses were consistent across FRα expression levels and prior PARPi exposure. Median duration of response (DOR) and median progression-free survival (PFS) were not reached at median follow-ups of 6.2 and 10.2 months, respectively.

Chrisann Kyi, MD, Gynecologic Medical Oncologist & Early Drug Development Specialist at Memorial Sloan Kettering Cancer Center: "The durable and robust responses we've seen in patients with platinum-sensitive ovarian cancer are important, particularly in a PARPi pretreated population, where the response rate seen with Sofe-M exceeds what has been reported in published platinum re-challenge studies. The observed safety profile and low discontinuation rates, combined with early efficacy results, support the continued investigation of Sofe-M as a potentially meaningful new option for patients."

Sofe-M plus bevacizumab demonstrated a safety profile consistent with the known profiles of each medicine. No new safety signals were observed. The most common treatment-emergent adverse events (TEAEs) across all patients included epistaxis (73%), nausea (73%), anemia (58%), neutropenia (55%), and fatigue (52%). The most common Grade ≥3 TEAEs were neutropenia (42%) and anemia (24%); febrile neutropenia occurred in 3% of patients, and G-CSF prophylaxis was not mandated. Any-grade neuropathy occurred in 9% of patients, with no Grade ≥3 events. Dose reductions occurred in 42% of patients, and 6% discontinued treatment due to an adverse event.

The FRAmework-01 program is evaluating Sofe-M in three global Phase 3 trials across both platinum-resistant and platinum-sensitive ovarian cancer: Part A tests Sofe-M as monotherapy in platinum-resistant disease; Part B tests Sofe-M plus bevacizumab in platinum-sensitive disease that progressed on or within six months of completing a PARPi; and Part C tests Sofe-M plus bevacizumab in PARPi-naïve platinum-sensitive disease. The study is being conducted in partnership with the European Network for Gynaecological Oncological Trial groups (ENGOT - lead groups GINECO/NOGGO e.V.), the GOG Foundation (GOG), and the Asia-Pacific Gynecologic Oncology Trials Group (APGOT).

For more information on Lilly's oncology pipeline, click here.

Frequently Asked Questions

What is sofetabart mipitecan (Sofe-M)? Sofetabart mipitecan (Sofe-M) is an investigational folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC) being studied for the treatment of ovarian cancer and other solid tumors. It is designed to selectively bind to cancer cells expressing FRα and deliver a topoisomerase I inhibitor payload directly to those cells. What is an antibody-drug conjugate? An antibody-drug conjugate (ADC) is a type of medicine that pairs an antibody with a cell-killing payload. The antibody is designed to recognize and bind to a specific protein found on the surface of cancer cells, and the payload is released once the ADC reaches its target, allowing the medicine to attack cancer cells while limiting exposure to healthy tissue.1 How is Sofe-M different from other FRα-targeted ADCs? Sofe-M is designed to target FRα across a broad range of expression levels, including in tumors with lower FRα expression. In this Phase 1 study, Sofe-M plus bevacizumab showed a confirmed objective response rate of 79.3% in platinum-sensitive ovarian cancer (PSOC), with consistent activity across FRα expression levels and regardless of prior PARP inhibitor exposure. Earlier studies in platinum-resistant ovarian cancer (PROC) also demonstrated responses observed across all FRα expression levels and in patients previously treated with mirvetuximab soravtansine (MIRV).2 These results are being further evaluated in Lilly's ongoing Phase 3 FRAmework-01 program, which is studying Sofe-M across both platinum-resistant and platinum-sensitive ovarian cancer. What are the results with sofetabart mipitecan (Sofe-M) in the treatment of platinum-sensitive ovarian cancer (PSOC)?The Phase 1 study demonstrated encouraging clinical activity, including a confirmed objective response rate (cORR) of 79.3% and a disease control rate (DCR) of 100%, in heavily pretreated patients with platinum-sensitive ovarian cancer. Activity was observed across FRα expression levels and regardless of prior PARP inhibitor exposure. Median duration of response (DOR) and median progression-free survival (PFS) were not reached at median follow-ups of 6.2 and 10.2 months, respectively. Sofetabart mipitecan (Sofe-M) plus bevacizumab demonstrated a safety profile consistent with the known profiles of each medicine, with no new safety signals observed and a low rate of discontinuation due to adverse events (6%). These findings support continued investigation of Sofe-M in the ongoing Phase 3 FRAmework-01 trial. In this study Sofe-M was dosed at 4 mg/kg. Why is it dosed at 3mg/kg in the Phase 3 FRAmework-01 trial? The 3 mg/kg dose of Sofe-M was selected as the recommended phase 3 dose (RP3D), based on analysis of the safety, efficacy and PK data as monotherapy. The ORR was comparable between the two doses, with ORRs of 59.0% (95% CI 42.1, 74.4) and 58.8% (95% CI 32.9, 81.6), at 4 mg/kg and 3mg/kg doses, respectively. Safety signals were higher at 4 mg/kg versus 3 mg/kg, with Grade ≥3 TRAEs at 56.4% vs 35.3% and dose reductions of 41.0% vs 23.5%. What are historical clinical trial results for standard of care in platinum-sensitive ovarian cancer (PSOC)? For patients who recur after platinum-based chemotherapy and PARP inhibitor (PARPi) maintenance, published real world data on subsequent platinum re-challenge have shown modest response rates, with an objective response rate (ORR) of 41.9%.3 Other studies of platinum-based regimens, such as OCEANS, were conducted prior to the routine use of PARPi maintenance and did not include patients previously treated with a PARPi,4 a population that now represents a majority of patients with recurrent PSOC, including those enrolled in Sofe-M's Phase 1 study. What is platinum-sensitive ovarian cancer (PSOC)? Platinum-sensitive ovarian cancer (PSOC) is characterized as ovarian cancer that comes back more than six months after platinum-based chemotherapy. While people with PSOC can often be treated with platinum again, the disease tends to return, and each recurrence can leave fewer treatment options and shorter remissions.5 What is the current unmet need in platinum-sensitive ovarian cancer (PSOC)? The standard of care for PSOC has remained largely unchanged for more than a decade, even as understanding of which patients benefit from it has evolved. Approximately 50% of PSOC patients have HRD-positive tumors, meaning their tumors carry a specific DNA-repair deficiency.6 These patients tend to have longer progression-free survival with upfront platinum-based chemotherapy plus a PARP inhibitor (PARPi).6 However, when these patients do recur after PARPi maintenance, response rates to subsequent platinum-based treatment are modest.6 Patients with non-HRD-positive tumors see minimal benefit from PARPi to begin with and generally have a poorer prognosis overall.6 Despite these different outcomes between HRD-positive and HRD-negative patients, treatment approaches for PSOC have not meaningfully changed to reflect that distinction. What is the difference between platinum-resistant (PROC) and platinum-sensitive ovarian cancer (PSOC)?The difference comes down to timing. If ovarian cancer returns more than six months after platinum-based chemotherapy, it's considered platinum-sensitive, and patients often respond well to platinum treatment again. If the cancer returns within six months, or continues growing during treatment, it's considered platinum-resistant, and platinum-based chemotherapy is generally no longer effective. Because platinum resistance tends to develop gradually, each recurrence can bring a shorter remission, even while a patient's disease is still classified as platinum-sensitive.6 What is folate receptor alpha (FRα), and why is FRα expression level important in treating ovarian cancer? FRα is expressed in almost all ovarian cancers, at much higher levels than in healthy tissue, making it a target that can help direct treatment to tumor cells.7 FRα expression level refers to the amount of the protein present on a tumor and may influence eligibility for or response to certain FRα-targeted therapies.7 How is the FRAmework-01 clinical trial designed? FRAmework-01 is a global, three-part Phase 3 trial studying sofetabart mipitecan (Sofe-M) across both platinum-resistant and platinum-sensitive ovarian cancer in a single program: Part A tests Sofe-M as monotherapy in platinum-resistant disease; Part B tests Sofe-M plus bevacizumab in platinum-sensitive disease that progressed on or within six months of completing a PARPi; and Part C tests Sofe-M plus bevacizumab in PARPi-naïve platinum-sensitive disease. The trial's main measure of success across all three parts is how long patients go without their cancer progressing. The study is being conducted in partnership with the European Network for Gynaecological Oncological Trial groups (ENGOT - lead groups GINECO/NOGGO e.V.), the GOG Foundation (GOG), and the Asia-Pacific Gynecologic Oncology Trials Group (APGOT). Enrollment is ongoing globally with first registrational dose in Q4 2025 for PROC and in Q1 2026 for PSOC.

About Ovarian Cancer

Ovarian cancer is the sixth leading cause of cancer death among women in the United States.8 While most patients initially respond to platinum-based chemotherapy, approximately 70% will experience recurrence, leading to progressively shorter remission periods with each subsequent treatment.6 When cancer recurs during or within six months of platinum therapy, known as platinum-resistant disease, patients face limited treatment options.6,9

About Sofetabart Mipitecan

Sofetabart mipitecan (Sofe-M; LY4170156) is composed of an Fc-silent, folate receptor alpha (FRα) specific humanized monoclonal antibody linked to exatecan, a topoisomerase I inhibitor, via a proprietary cleavable polysarcosine linker (PSARlink). Sofe-M was designed to target FRα across all expression levels with improved therapeutic index. FRα is a cell-surface glycoprotein encoded by the gene FOLR1 that binds to the essential nutrients folic acid and reduced folates, bringing them into cells to facilitate cell division and growth. FRα is overexpressed in many solid tumors such as ovarian and endometrial cancers. Sofe-M has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for platinum-resistant ovarian cancer (PROC) and is currently being evaluated in the Phase 3 FRAmework-01 program. The study is being conducted in partnership with the European Network for Gynaecological Oncological Trial groups (ENGOT - lead groups GINECO/NOGGO e.V.), the GOG Foundation (GOG), and the Asia-Pacific Gynecologic Oncology Trials Group (APGOT).  

About FRAmework-01

FRAmework-01 (NCT07213804) is a Phase 3, randomized, open-label, three-part study evaluating sofetabart mipitecan (Sofe-M; LY4170156) in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. Part A tests Sofe-M as monotherapy in platinum-resistant disease; Part B tests Sofe-M plus bevacizumab in platinum-sensitive disease that progressed on or within six months of completing a PARPi; and Part C tests Sofe-M plus bevacizumab in PARPi-naïve platinum-sensitive disease. The primary endpoint is progression-free survival (PFS), assessed by the investigator in Part A and by blinded independent central review (BICR) in Parts B and C. Key secondary endpoints are overall survival, objective response rate, duration of response, and safety.  The FRAmework-01 study is in partnership with the European Network for Gynecological Oncological Trial groups (ENGOT - lead groups GINECO/NOGGO e.V.), the GOG Foundation (GOG), and the Asia-Pacific Gynecologic Oncology Trials Group (APGOT).

More information on FRAmework-01 can be found on clinicaltrials.gov.

References

Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat Rev Clin Oncol. 2021;18(6):327-344. doi:10.1038/s41571-021-00470-8 2. Ray-Coquard, et al. Sofetabart mipitecan, an antibody drug conjugate targeting folate receptor alpha, in high grade ovarian cancer: Results from the first-in-human phase 1 study, Annals of Oncology (2026), doi: https://doi.org/10.1016/j.annonc.2026.10.001. Romeo M, Gil-Martín M, Gaba L, et al. Multicenter real-world data of subsequent chemotherapy after progression to PARP inhibitors in a maintenance relapse setting. Cancers (Basel). 2022;14(18):4414. Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30(17):2039-2045. Lesnock JL, Temin S, Bouberhan S, et al. Systemic Treatment of Ovarian Cancer Recurrence: ASCO Living Guideline, Version 2026.1.0. J Clin Oncol. Published online July 13, 2026. doi:10.1200/JCO-26-01591. Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA Cancer J Clin. 2019;69(4):280-304. doi:10.3322/caac.21559. Bax HJ, Chauhan J, Stavraka C, et al. Folate receptor alpha in ovarian cancer tissue and patient serum is associated with disease burden and treatment outcomes. Br J Cancer. 2023;128(2):342-353. doi:10.1038/s41416-022-02031-x. American Cancer Society. Cancer Facts for Women. Accessed September 9, 2026. https://www.cancer.org/cancer/risk-prevention/understanding-cancer-risk/cancer-facts/cancer-facts-for-women.html. Colombo N, Sessa C, du Bois A, et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Ann Oncol. 2019;30(5):672-705. doi: 10.1093/annonc/mdz062. About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram, and LinkedIn. P-LLY

© Lilly USA, LLC 2026. ALL RIGHTS RESERVED.

MSK Disclosure: Dr. Kyi has financial interests related to Eli Lilly and Company.             

Trademarks and Trade Names
All trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are references in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about sofetabart mipitecan plus bevacizumab and reflects Lilly's current beliefs and expectations. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of drug research, development, and commercialization. Among other things, there is no guarantee that planned or ongoing studies will be completed as planned, that future study results will be consistent with study results to date, that any of these therapies will prove to be a safe and effective treatment or receive regulatory approval, or that Lilly will execute its strategy as expected. For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.

SOURCE Eli Lilly and Company

The Chemours Company Securities Fraud Class Action Result of Overstatement of Refrigerant Aftermarket Demand and 18% Stock Decline - Investors may Contact Lewis Kahn, Esq., at Kahn Swick & Foti, LLCPR Newswire

NEW YORK and NEW ORLEANS, Oct. 23, 2026

, /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until December 7, 2026 to file lead plaintiff applications in a securities class action lawsuit against The Chemours Company ("Chemours" or the "Company") (NYSE: CC), if they purchased or otherwise acquired the Company's securities between February 20, 2026 and August 4, 2026, inclusive (the "Class Period"). This action is pending in the United States District Court for the District of Delaware.

What You May Do

If you purchased securities of Chemours as above and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-833-538-3666 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nyse-cc/ to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by December 7, 2026.

>>>CLICK HERE for more information

About the Lawsuit

Chemours and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.

On August 4, 2026, post-market, the Company announced its 2Q 2026 financial results and cut its full-year adjusted EBITDA guidance to $775–$825 million, down from $800–$900 million. On the earnings call the next morning, CEO Denise Dignam admitted that "[a]s a result of the initial channel fill, aftermarket customers built additional inventory, creating an oversupplied channel heading into 2026." CFO Shane Hostetter added that, "from the Q2 and Q3 perspective, there's probably about $65 million of aftermarket sales that . . . probably should have been allocated to more of this year."

On this news, the price of Chemours' shares fell $3.34 per share, or 18.63%, to close at $14.59 per share on August 5, 2026.

The case is Darcy v. The Chemours Company, et al., No. 26-cv-01299.

>>>To Learn More, Click HERE

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.

TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services

To learn more about KSF, you may visit www.ksfcounsel.com.

>>>For More Information about the case, Click HERE

Contact:
Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
[email protected]
1-833-538-3666
1100 Poydras St., Suite 960
New Orleans, LA 70163

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn

View original content to download multimedia:https://www.prnewswire.com/news-releases/the-chemours-company-securities-fraud-class-action-result-of-overstatement-of-refrigerant-aftermarket-demand-and-18-stock-decline---investors-may-contact-lewis-kahn-esq-at-kahn-swick--foti-llc-302918520.html

SOURCE Kahn Swick & Foti, LLC

-

Investigation follows the October 2, 2026 disclosure regarding Integra LifeSciences Holdings Corporation; investors who lost money may have claims to recover their losses

LOS ANGELES--(BUSINESS WIRE)--Investors who lost money on Integra LifeSciences Holdings Corporation ("Integra" or the "Company") stock may have claims to recover their losses. Glancy Prongay Wolke & Rotter LLP ("Glancy") today announced a securities fraud investigation on behalf of Integra LifeSciences Holdings Corporation (NASDAQ: IART) investors into whether the Company may have violated the federal securities laws. The investigation follows the October 2, 2026 disclosure regarding Integra LifeSciences Holdings Corporation.

Investors who lost money on Integra LifeSciences Holdings Corporation securities can submit their Integra LifeSciences Holdings Corporation loss information to learn about potentially pursuing claims to recover their losses.

Key facts in the Integra LifeSciences Holdings Corporation investigation

Disclosure date: October 2, 2026Stock price decline: $3.41 per share, or 21.2%Closing price after the decline: $12.68 on October 2, 2026What happened?

On October 2, 2026, Integra announced updated full year guidance and preliminary third quarter results. The Company disclosed, among other things, that due to a July flood at its Cincinnati manufacturing facility, “disruption negatively impacted third quarter revenue by approximately $7 million and is expected to negatively impact fourth quarter revenue by approximately $15 million to $20 million.” Integra also slashed its 2026 revenue guidance by approximately $30.5 million at the midpoint. 

On this news, Integra shares fell $3.41 or 21.2%, closing at $12.68 on October 2, 2026, thereby injuring investors.

Then, on October 21, 2026, Integra reported final third quarter results. Among other items, the Company disclosed “the Cincinnati disruption proved more significant than initially expected.” The Company announced it expected fourth quarter revenue of $413 million to $433 million (down 0.5% to 5.2%). The Company further disclosed “more measured expectations for portions of our Tissue Reconstruction business” in part because “growth in Tissue Reconstruction did not materialize as anticipated.”

On this news, Integra’s stock fell $1.49 or 11.18% to close at $11.84 on October 21, 2026, thereby injuring investors further.

"The price of Integra LifeSciences Holdings Corporation shares fell 21.2% following the October 2, 2026 disclosure that Integra had cut its 2026 revenue guidance by approximately $30.5 million at the midpoint and said a July flood at its Cincinnati manufacturing facility reduced third quarter revenue by about $7 million and would reduce fourth quarter revenue by $15 million to $20 million. Investors who suffered losses deserve to know whether they were given complete and accurate information prior to the disclosure, and our investigation seeks to answer that question," said Charles H. Linehan, Partner at Glancy Prongay Wolke & Rotter LLP.

What's the next step?

Glancy is investigating potential claims on behalf of Integra LifeSciences Holdings Corporation investors. Investors who lost money can contact Glancy about the Integra LifeSciences Holdings Corporation investigation, email [email protected], or call 310-201-9150 (toll-free: 888-773-9224).

Frequently Asked Questions

Who is eligible? Investors who bought Integra LifeSciences Holdings Corporation securities and lost money may have claims, and can contact Glancy to learn whether they are affected by the Integra LifeSciences Holdings Corporation investigation.

What is a securities fraud investigation? In the Integra LifeSciences Holdings Corporation investigation, Glancy is reviewing whether the Company or its executives may have made false or misleading statements to investors in violation of the federal securities laws.

Has a lawsuit been filed? This release announces Glancy's investigation, not a lawsuit. If a securities class action is later filed against Integra LifeSciences Holdings Corporation, investors may have the opportunity to seek appointment as lead plaintiff.

Does it cost anything to contact Glancy or participate in this investigation? Glancy represents Integra LifeSciences Holdings Corporation investors on a contingency fee basis, so investors pay no attorneys' fees out of pocket. Any attorneys' fees and litigation expenses are paid only from a recovery, if one is obtained, and are subject to court approval.

Why work with Glancy on the Integra LifeSciences Holdings Corporation investigation? Glancy Prongay Wolke & Rotter LLP is a premier law firm with decades of experience representing investors and consumers in securities litigation and other complex class action litigation. Contact Glancy about the Integra LifeSciences Holdings Corporation investigation. Prior results do not guarantee a similar outcome.

Whistleblower notice

Persons with non-public information about Integra LifeSciences Holdings Corporation should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program. Under the program, whistleblowers who provide original information that leads to a successful SEC enforcement action may receive awards of 10 to 30 percent of the sanctions collected, when those sanctions exceed $1 million. For more information, contact Charles H. Linehan at 310-201-9150 or 888-773-9224, or email [email protected].

About Glancy Prongay Wolke & Rotter LLP

Glancy was named one of Law360's Securities Groups of the Year and ranked second in total investor recoveries by ISS Securities Class Action Services in 2025.

Glancy's successes have been widely covered by leading news and industry publications, including The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron's, Investor's Business Daily, Forbes, and Money.

Prior results do not guarantee a similar outcome.

Related links

Integra LifeSciences Holdings Corporation investigation page, Glancy Prongay Wolke & Rotter LLPIntegra Q3 Financial ResultsIntegra LifeSciences Holdings Corporation SEC filings index, EDGARSEC Whistleblower ProgramGlancy Prongay Wolke & Rotter LLPThis press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

More News From Glancy Prongay Wolke & Rotter LLP

Back to Newsroom

Research Will Use Lunit's AI-powered Pathology Platform to Analyze H&E Whole-Slide Images and Generate Scalable Insights into Tumor Microenvironment Biology

, /PRNewswire/ -- Lunit Inc. (KRX: 328130) and Summit Therapeutics Inc. (NASDAQ: SMMT) today announced a research agreement to evaluate the use of Lunit SCOPE IO, Lunit's AI-powered pathology platform, for tumor microenvironment analysis in support of Summit's immuno-oncology development programs with ivonescimab.

Lunit and Summit Therapeutics The effort will focus on applying Lunit SCOPE IO to hematoxylin and eosin-stained (H&E) whole-slide images to characterize tumor microenvironment features. The companies aim to explore how AI-powered pathology analysis can support biomarker discovery, patient stratification or selection, and a deeper biological understanding of response to ivonescimab therapies.

Summit is developing ivonescimab, a novel, potential first-in-class investigational PD-1 / VEGF bispecific antibody, in several solid tumors. Lunit SCOPE IO is designed to support immuno-oncology research and biomarker development through AI-powered analysis of H&E slides, enabling scalable assessment of tumor microenvironment features without requiring additional stains or assays.

"Understanding the tumor microenvironment is increasingly important as immuno-oncology moves beyond single-axis checkpoint inhibition toward more complex mechanisms and combinations," said Allen Yang, MD, PhD, Chief Research and Development Strategy Officer of Summit. "We are pleased to work with Lunit to explore how AI-powered pathology can help generate deeper, more scalable insights from routine tissue samples and inform the continued development of ivonescimab."

"Summit is at the forefront of next-generation immuno-oncology development, and we are excited to support its efforts with Lunit SCOPE IO," said Brandon Suh, Lunit CEO. "By extracting quantitative, spatially resolved immune and tumor microenvironment features from standard H&E slides, we believe SCOPE IO can help biopharma partners better understand which patients may benefit from immuno-oncology therapies and why."

This agreement reflects the growing importance of computational pathology in oncology drug development. Routine H&E slides contain rich information about tumor architecture, immune infiltration, stromal organization, and spatial interactions within the tumor microenvironment. However, traditional manual assessment can be difficult to scale and may not fully capture the quantitative and spatial complexity of the tumor-immune interface. AI-powered analysis offers the potential to convert these routinely generated pathology images into reproducible, high-dimensional biomarker data.

The companies expect the work to generate tumor microenvironment insights that may inform future translational research, exploratory biomarker strategies, and clinical development planning. No clinical outcome data are being announced as part of this release.

 *Lunit SCOPE products are for research use only. Not for use in diagnostic procedures or decisions.

About Ivonescimab

Ivonescimab, known as SMT112 in Summit's license territories, North America, South America, Europe, the Middle East, Africa, and Japan, and as AK112 outside of Summit's license territories, is a novel, potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. By design, ivonescimab displays unique cooperative binding to each of its intended targets with multifold higher affinity to PD-1 when in the presence of VEGF.

This design is intended to differentiate ivonescimab as there is potentially higher expression (presence) of both PD-1 and VEGF in tumor tissue and the tumor microenvironment (TME) as compared to normal tissue in the body. Summit believes ivonescimab's specifically engineered tetravalent structure (four binding sites) enables higher avidity (accumulated strength of multiple binding interactions) in the TME (Zhong, et al, iScience, 2025). This tetravalent structure, the intentional novel design of the molecule, and bringing these two targets into a single bispecific antibody with cooperative binding qualities have the potential to direct ivonescimab to the tumor tissue versus healthy tissue. The intent of ivonescimab's design, together with a half-life of 6 to 7 days after the first dose (Zhong, et al, iScience, 2025) increasing to approximately 10 days at steady state dosing, is to improve upon previously established efficacy thresholds, side effects, and safety profiles associated with prior approved drugs to these targets.

Ivonescimab was invented by Akeso Inc. (HKEX Code: 9926.HK) and is currently utilized in multiple Phase III clinical trials. Over 5,000 patients have been treated with ivonescimab in clinical studies globally and over 100,000 patients when considering those treated in a commercial setting in China, as noted by Akeso.

There are currently 17 Phase III clinical studies that are either announced, ongoing, or have been completed studying ivonescimab, five of which are Summit-sponsored global studies, two of which are studies sponsored by cooperative groups, and 10 of which are being or have been conducted in China by Akeso. Summit began its clinical development of ivonescimab in NSCLC (HARMONi, HARMONi-3, HARMONi-7) and expanded its sponsored Phase III clinical development program into colorectal cancer (CRC; HARMONi-GI3) and urothelial carcinoma (bladder cancer; HARMONi-GU1). The two cooperative studies are in head and neck squamous cell carcinoma (HNSCC; ILLUMINE) and biliary tract cancer (BTC; EA2251).

Five Phase III ivonescimab clinical trials have read out to date, all five with positive data. Four of these five studies are in NSCLC and one is in BTC. In addition to Summit's positive HARMONi study in NSCLC, Akeso has had positive read-outs in four single-region (China), randomized Phase III clinical trials, HARMONi-A, HARMONi-2, HARMONi-6 (each in NSCLC), and HARMONi-GI1 (in BTC) for ivonescimab, including a statistically significant overall survival benefit in all four studies from China.

Akeso is actively conducting additional Phase III clinical studies in settings outside of NSCLC and biliary-tract cancer, including triple-negative breast cancer, head and neck squamous cell carcinoma, small cell lung cancer, colorectal cancer, and pancreatic cancer.

Ivonescimab is an investigational therapy that is not approved by any regulatory authority in Summit's license territories, including the United States and Europe. Ivonescimab was initially approved for marketing authorization in China in May 2024.

About Lunit

Founded in 2013, Lunit (KRX: 328130) is a global leader on a mission to conquer cancer through AI. Our clinically validated solutions span medical imaging, breast health, and biomarker analysis, empowering earlier detection, smarter treatment decisions, and more precise outcomes across the cancer care continuum.

Lunit offers a comprehensive suite spanning risk prediction and early detection to precision oncology. Our FDA-cleared Lunit INSIGHT Breast Suite and breast health solutions support cancer screening in thousands of medical institutions worldwide, while the Lunit SCOPE platform is used in research partnership with global pharma and laboratory leaders for biomarker research, and companion diagnostic development.

Trusted by over 10,000 sites in more than 65 countries, Lunit combines deep medical expertise with continuously evolving datasets to deliver measurable impact for patients, clinicians, and researchers alike. Headquartered in Seoul with global offices, Lunit is driving the worldwide fight against cancer. Learn more at lunit.io.

About Summit Therapeutics Inc.

Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs.

Summit was founded in 2003 and the company's shares are listed on the Nasdaq Global Market (symbol "SMMT"). Summit is headquartered in Miami, Florida, with additional offices in Palo Alto, California, Princeton, New Jersey, Dublin, Ireland, and Oxford, UK.

For more information, please visit https://www.smmttx.com and follow Summit on X @SMMT_TX.

Lunit Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding the expected benefits of the collaboration, the potential use of AI-powered pathology in immuno-oncology development, and the potential application of tumor microenvironment analysis in biomarker research and clinical development. These statements are based on current expectations and involve risks and uncertainties that could cause actual results to differ materially. Neither company undertakes any obligation to update these forward-looking statements, except as required by law.

Summit Forward-Looking Statements

Any statements in this press release about the Company's future expectations, plans and prospects, including but not limited to, statements about dilution to existing stockholders and potential adverse effects on the market price of the Company's common stock, including from future sales by AstraZeneca, the Company's broad discretion over the use of proceeds, and the possibility that the proceeds will not be sufficient to fund operations as long as anticipated, AstraZeneca's ownership and contractual rights, including Third Party acquisition participation, and registration rights, and potential conflicts of interest, the completion of the Private Placement does not depend on the parties entering into a definitive collaboration agreement, the Company's reliance on AstraZeneca for the supply of AstraZeneca's products and other contributions to the clinical trials, the clinical and preclinical development of the Company's product candidates, entry into and actions related to the Company's partnership with Akeso Inc. and other collaborations, the intended use of the net proceeds from the private placements, the Company's anticipated spending and cash runway, the therapeutic potential of the Company's product candidates, the potential commercialization of the Company's product candidates, the timing of initiation, completion and availability of data from clinical trials, the potential submission of applications for marketing approvals, the expected timing of BLA submissions or FDA decisions, potential acquisitions, statements about the previously disclosed At-The-Market equity offering program ("ATM Program"), the expected proceeds and uses thereof, the Company's estimates regarding stock-based compensation, and other statements containing the words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the Company's ability to sell shares of our common stock under the ATM Program, the conditions affecting the capital markets, general economic, industry, or political conditions, including the effects of geopolitical developments, domestic and foreign trade policies, and monetary policies, the results of our evaluation of the underlying data in connection with the development and commercialization activities for ivonescimab, the outcome of discussions with regulatory authorities, including the Food and Drug Administration, the uncertainties inherent in the initiation of future clinical trials, availability and timing of data from ongoing and future clinical trials, the results of such trials, and their success, global public health crises, that may affect timing and status of our clinical trials and operations, whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials or preclinical studies will be indicative of the results of later clinical trials, whether business development opportunities to expand the Company's pipeline of drug candidates, including without limitation, through potential acquisitions of, and/or collaborations with, other entities occur, expectations for regulatory approvals, laws and regulations affecting government contracts and funding awards, availability of funding sufficient for the Company's foreseeable and unforeseeable operating expenses and capital expenditure requirements and other factors discussed in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of filings that the Company makes with the Securities and Exchange Commission. Summit defines a "positive study" as a clinical study with one or more prespecified primary endpoints in which one of those endpoints achieves a statistically significant benefit according to the protocol or statistical analysis plan. Any change to our ongoing trials could cause delays, affect our future expenses, and add uncertainty to our commercialization efforts, as well as to affect the likelihood of the successful completion of clinical development of ivonescimab. Accordingly, readers should not place undue reliance on forward-looking statements or information. In addition, any forward-looking statements included in this press release represent the Company's views only as of the date of this release and should not be relied upon as representing the Company's views as of any subsequent date. The Company specifically disclaims any obligation to update any forward-looking statements included in this press release.

SOURCE Lunit Inc.

For the quarter ended September 2026, Halliburton (HAL - Free Report) reported revenue of $5.7 billion, up 1.8% over the same period last year. EPS came in at $0.60, compared to $0.58 in the year-ago quarter.

The reported revenue represents a surprise of +1.98% over the Zacks Consensus Estimate of $5.59 billion. With the consensus EPS estimate being $0.58, the EPS surprise was +3.45%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Halliburton performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Revenue- Latin America: $1.12 billion versus $1.06 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +12.7% change.Revenue- Europe/Africa/CIS: $1.02 billion versus the three-analyst average estimate of $924.3 million. The reported number represents a year-over-year change of +22.7%.Revenue- North America: $2.16 billion versus the three-analyst average estimate of $2.29 billion. The reported number represents a year-over-year change of -8.6%.Revenue- Middle East/Asia: $1.41 billion versus $1.3 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -0.5% change.Revenue- Drilling and Evaluation: $2.61 billion compared to the $2.41 billion average estimate based on five analysts. The reported number represents a change of +10% year over year.Revenue- Completion and Production: $3.09 billion compared to the $3.16 billion average estimate based on five analysts. The reported number represents a change of -4.2% year over year.Operating income- Completion and Production: $457 million versus the five-analyst average estimate of $515.8 million.Operating income- Drilling and Evaluation: $391 million compared to the $338.22 million average estimate based on five analysts.Operating income- Corporate and other: $-75 million versus $-102.5 million estimated by two analysts on average.View all Key Company Metrics for Halliburton here>>>

Shares of Halliburton have returned +1.3% over the past month versus the Zacks S&P 500 composite's -1.2% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

VICI Properties Inc. (VICI - Free Report) ended the recent trading session at $23.76, demonstrating a -1.08% change from the preceding day's closing price. This change lagged the S&P 500's daily loss of 0.52%. Elsewhere, the Dow saw a downswing of 1.24%, while the tech-heavy Nasdaq depreciated by 0.21%.

Heading into today, shares of the company had gained 3.22% over the past month, outpacing the Finance sector's loss of 0.78% and the S&P 500's loss of 1.21%.

Investors will be eagerly watching for the performance of VICI Properties Inc. in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on October 28, 2026. It is anticipated that the company will report an EPS of $0.62, marking a 3.33% rise compared to the same quarter of the previous year. Meanwhile, our latest consensus estimate is calling for revenue of $1.06 billion, up 5.67% from the prior-year quarter.

For the full year, the Zacks Consensus Estimates project earnings of $2.47 per share and a revenue of $4.22 billion, demonstrating changes of +3.78% and +5.26%, respectively, from the preceding year.

Investors should also note any recent changes to analyst estimates for VICI Properties Inc. Recent revisions tend to reflect the latest near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.

Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.

Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. VICI Properties Inc. is currently sporting a Zacks Rank of #2 (Buy).

Looking at valuation, VICI Properties Inc. is presently trading at a Forward P/E ratio of 9.73. For comparison, its industry has an average Forward P/E of 11.85, which means VICI Properties Inc. is trading at a discount to the group.

The REIT and Equity Trust - Other industry is part of the Finance sector. With its current Zacks Industry Rank of 95, this industry ranks in the top 39% of all industries, numbering over 250.

The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.

For the quarter ended September 2026, Kinder Morgan (KMI - Free Report) reported revenue of $4.53 billion, up 9.3% over the same period last year. EPS came in at $0.35, compared to $0.29 in the year-ago quarter.

The reported revenue represents a surprise of +3.52% over the Zacks Consensus Estimate of $4.38 billion. With the consensus EPS estimate being $0.33, the EPS surprise was +6.06%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Kinder Morgan performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Realized weighted average oil price: $/68.65 versus the two-analyst average estimate of $/71.4.Realized weighted average NGL price: $/34.48 versus $/35.06 estimated by two analysts on average.Terminals - Liquids leasable capacity: 78.70 MMBBL versus the two-analyst average estimate of 78.60 MMBBL.NGL sales volumes - net: 9.88 millions of barrels of oil compared to the 9.8 millions of barrels of oil average estimate based on two analysts.CO2 sales volumes - net: 0.27 Bcf/D compared to the 0.30 Bcf/D average estimate based on two analysts.Total oil production - net: 27.07 millions of barrels of oil versus 28.2 millions of barrels of oil estimated by two analysts on average.Terminals - Bulk transload tonnage: 13.50 MMTon versus 12.65 MMTon estimated by two analysts on average.Segment EBDA- Natural gas Pipelines: $1.5 billion versus $1.41 billion estimated by three analysts on average.Segment EBDA- Terminals: $385 million compared to the $284.75 million average estimate based on three analysts.Segment EBDA- Products Pipelines: $172 million compared to the $290.54 million average estimate based on three analysts.Segment EBDA- CO2: $172 million versus the three-analyst average estimate of $195.07 million.View all Key Company Metrics for Kinder Morgan here>>>

Shares of Kinder Morgan have returned +7.9% over the past month versus the Zacks S&P 500 composite's -1.2% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

In the latest close session, CRH (CRH - Free Report) was down 1.78% at $84.89. This change lagged the S&P 500's 0.52% loss on the day. Elsewhere, the Dow saw a downswing of 1.24%, while the tech-heavy Nasdaq depreciated by 0.21%.

Coming into today, shares of the building material company had gained 2.94% in the past month. In that same time, the Construction sector lost 6.53%, while the S&P 500 lost 1.21%.

The investment community will be paying close attention to the earnings performance of CRH in its upcoming release. The company is slated to reveal its earnings on October 29, 2026. The company's earnings per share (EPS) are projected to be $2.14, reflecting a 3.17% decrease from the same quarter last year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $11.72 billion, up 5.87% from the year-ago period.

For the full year, the Zacks Consensus Estimates project earnings of $5.83 per share and a revenue of $39.6 billion, demonstrating changes of +4.67% and +5.75%, respectively, from the preceding year.

Investors might also notice recent changes to analyst estimates for CRH. These recent revisions tend to reflect the evolving nature of short-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.

Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.

The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 1.24% downward. As of now, CRH holds a Zacks Rank of #3 (Hold).

Looking at valuation, CRH is presently trading at a Forward P/E ratio of 14.83. This expresses a discount compared to the average Forward P/E of 17.08 of its industry.

Also, we should mention that CRH has a PEG ratio of 1.57. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. Building Products - Miscellaneous stocks are, on average, holding a PEG ratio of 1.5 based on yesterday's closing prices.

The Building Products - Miscellaneous industry is part of the Construction sector. This industry currently has a Zacks Industry Rank of 204, which puts it in the bottom 18% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.

In the latest trading session, KB Home (KBH - Free Report) closed at $47.05, marking a +1.86% move from the previous day. The stock exceeded the S&P 500, which registered a loss of 0.52% for the day. Meanwhile, the Dow experienced a drop of 1.24%, and the technology-dominated Nasdaq saw a decrease of 0.21%.

The homebuilder's shares have seen a decrease of 3.06% over the last month, surpassing the Construction sector's loss of 6.53% and falling behind the S&P 500's loss of 1.21%.

The investment community will be paying close attention to the earnings performance of KB Home in its upcoming release. It is anticipated that the company will report an EPS of $1.21, marking a 36.98% fall compared to the same quarter of the previous year. Meanwhile, the latest consensus estimate predicts the revenue to be $1.53 billion, indicating a 9.81% decrease compared to the same quarter of the previous year.

For the full year, the Zacks Consensus Estimates are projecting earnings of $3.26 per share and revenue of $5.02 billion, which would represent changes of -50% and -19.55%, respectively, from the prior year.

Investors should also note any recent changes to analyst estimates for KB Home. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.

Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.31% higher. KB Home presently features a Zacks Rank of #3 (Hold).

In terms of valuation, KB Home is currently trading at a Forward P/E ratio of 14.17. This represents a premium compared to its industry average Forward P/E of 13.01.

We can also see that KBH currently has a PEG ratio of 2.4. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Building Products - Home Builders was holding an average PEG ratio of 2.35 at yesterday's closing price.

The Building Products - Home Builders industry is part of the Construction sector. This industry currently has a Zacks Industry Rank of 234, which puts it in the bottom 5% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.

SPCX Space Exploration Technologies$147.49+$2.74 (+1.89%)

NASDAQ · As of 4:00 PM ET 10/23/26

Space Exploration Technologies (SPCX +1.89%), better known as SpaceX, a launch services, satellite broadband, and space infrastructure provider, closed at $147.49, up 1.89%. Premarket analyst upgrades and regular-session coverage of tower-lease talks helped keep investors focused on growth and mobile ambitions.

Trading volume reached 109.4 million shares, coming in nearly 1% above its three-month average of 99.4 million shares. Space Exploration Technologies IPO'd in 2026 and has fallen 8% since going public.

How the markets moved todayThe S&P 500 (^GSPC -0.52%) fell 0.52% to 7,623, while the Nasdaq Composite (^IXIC -0.21%) slipped 0.21% to 25,955. In aerospace, defense, and satellite communications, Rocket Lab (RKLB +2.69%) closed at $52.60, up 2.69%, and AST SpaceMobile (ASTS +2.63%) finished at $39.79, up 2.63%, as space-linked peers drew steady attention.

What this means for investorsOn Friday, Oct. 23, SpaceX captured a rare double upgrade from Wall Street. Phillip Securities analyst Glenn Thum upgraded shares from Sell to Buy, bypassing Hold entirely. He also tripled the price target from $75 to $250 per share, implying an impressive upside potential of over 70% from its recent trading levels.

The dramatic reversal from bear to bull was driven by SpaceX's blowout third-quarter earnings report, which highlighted the spectacular growth of the company's artificial intelligence division, called Super Intelligence (SI).

SpaceX's SI business hit sales of $7.6 billion in Q3, up from $813 million last year, helping to grow total revenue 161% year over year to $14.6 billion. CEO Elon Musk stated the company's annual recurring revenue could reach a range between $500 billion and $1 trillion by the end of 2027. SI's success contributed to the bullish sentiment from Phillip Securities.

SI isn't the only factor galvanizing shares. SpaceX is reportedly negotiating tower leases as it seeks at least 80,000 U.S. cell sites in a bid to broaden its wireless mobile addressable market. The news of intensifying carrier competition caused telecom stocks to drop.

Amazon (AMZN.O) CEO Andy Jassy said on Friday that Amazon Web Services' cloud computing capacity is ​largely sold out through 2027, with ‌significant commitments extending into 2028, on growing demand for AI infrastructure.

In a video podcast with Andreessen Horowitz co-founder ​Ben Horowitz and general partner Erik ​Torenberg, Jassy said Amazon is struggling ⁠to keep pace with the insatiable demand ​from AI labs and enterprises.

Earlier this year, Amazon had ​said it would spend about $220 billion in capital expenditure for 2026

Jassy said the company "could invest a lot more ​and it wouldn't be a bad use of ​capital," considering cloud-computing capacity for 2026 is already sold out

"2027 is ‌largely ⁠sold out. We always leave a certain amount for on demand and our inference service bedrock, or EC2, but largely sold ​out all ​the big ⁠chunks. A good chunk of 2028 is sold out," he said

EC2 ​is an AWS service that ​provides ⁠cloud servers for running applications, while Bedrock gives customers access to AI models to build ⁠generative ​AI applications

Amazon is scheduled ​to report third quarter results on October 29

TORONTO, Oct. 23, 2026 (GLOBE NEWSWIRE) -- BlackRock Asset Management Canada Limited (“BlackRock Canada”), an indirect, wholly-owned subsidiary of BlackRock, Inc. (“BlackRock”) (NYSE:BLK) announced today that it intends to terminate iShares Convertible Bond Index ETF (the “Terminating Fund”), based on an ongoing process to review its product lineup. The Terminating Fund will terminate on or about January 21, 2027 (the “Termination Date”).

Terminating Fund NameTickeriShares Convertible Bond Index ETFCVD
BlackRock Canada expects that the units of the Terminating Fund will cease trading on the Toronto Stock Exchange (the “TSX”) and be voluntarily delisted from the TSX on or about January 18, 2027. In connection with the termination of the Terminating Fund, the distribution reinvestment plan, pre-authorized cash contribution plan and the systematic withdrawal plan of the Terminating Fund will be terminated on or about November 23, 2026.

The final monthly distribution is expected to be declared on or about December 21, 2026 and be paid on or about January 5, 2027.

In connection with the termination, the assets of the Terminating Fund will be liquidated. BlackRock Canada expects that the Terminating Fund's portfolio assets may mature or be sold for cash in advance of the Termination Date, resulting in the Terminating Fund deviating from its investment objectives and strategies in a manner consistent with liquidation. As soon as practicable following the Termination Date, the liquidation proceeds will be distributed, after paying or providing for all liabilities and obligations of the Terminating Fund, pro rata among unitholders of record of the Terminating Fund on the Termination Date. Following the termination and distributions described above, the Terminating Fund will be dissolved. BlackRock Canada will issue an additional press release on or about the Termination Date confirming final details of the termination.

About BlackRock

BlackRock’s purpose is to help more and more people experience financial well-being. As a fiduciary to investors and a leading provider of financial technology, we help millions of people build savings that serve them throughout their lives by making investing easier and more affordable. For additional information on BlackRock, please visit www.blackrock.com/corporate.

About iShares

iShares unlocks opportunity across markets to meet the evolving needs of investors. With more than twenty-five years of experience, a global line-up of more than 1,800 exchange traded funds (ETFs) and US$6.4 trillion in assets under management as of September 30, 2026, iShares continues to drive progress for the financial industry. iShares funds are powered by the expert portfolio and risk management of BlackRock.

iShares® ETFs are managed by BlackRock Asset Management Canada Limited.

Commissions, trailing commissions, management fees and expenses all may be associated with investing in iShares ETFs. Please read the relevant prospectus before investing. The funds are not guaranteed, their values change frequently and past performance may not be repeated. Tax, investment and all other decisions should be made, as appropriate, only with guidance from a qualified professional.

Contact for Media:
Sydney Punchard
Email: [email protected]

In the latest trading session, Intuit (INTU - Free Report) closed at $343.39, marking a -3.24% move from the previous day. The stock's performance was behind the S&P 500's daily loss of 0.52%. Meanwhile, the Dow experienced a drop of 1.24%, and the technology-dominated Nasdaq saw a decrease of 0.21%.

The stock of maker of TurboTax, QuickBooks and other accounting software has risen by 28.06% in the past month, leading the Computer and Technology sector's loss of 7.7% and the S&P 500's loss of 1.21%.

Analysts and investors alike will be keeping a close eye on the performance of Intuit in its upcoming earnings disclosure. The company is expected to report EPS of $2.47, down 26.05% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $4.3 billion, up 10.81% from the prior-year quarter.

For the full year, the Zacks Consensus Estimates project earnings of $23.5 per share and a revenue of $23.39 billion, demonstrating changes of -3.17% and +9.07%, respectively, from the preceding year.

Investors might also notice recent changes to analyst estimates for Intuit. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.

Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.

The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.03% upward. Intuit is currently sporting a Zacks Rank of #2 (Buy).

In terms of valuation, Intuit is currently trading at a Forward P/E ratio of 15.1. For comparison, its industry has an average Forward P/E of 17.66, which means Intuit is trading at a discount to the group.

Also, we should mention that INTU has a PEG ratio of 1.15. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. As the market closed yesterday, the Computer - Software industry was having an average PEG ratio of 1.49.

The Computer - Software industry is part of the Computer and Technology sector. This industry, currently bearing a Zacks Industry Rank of 55, finds itself in the top 23% echelons of all 250+ industries.

The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

To follow INTU in the coming trading sessions, be sure to utilize Zacks.com.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This innovative software-as-a-service firm upped its user base +22% year over year. That rate is increasing and margins are expanding as AI efficiencies take effect. Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.

Free: See Our Top Stock And 4 Runners Up

Hershey’s is trying to win over health-conscious consumers with a new protein powder — and figure out how to get people on weight-loss drugs snacking again.

The 132-year-old candy company is working to entice consumers who have soured on sweets with a protein powder coming out in January.

With shares recently hitting a 52-week low, Hershey’s CEO Kirk Tanner has reportedly been talking one-on-one with consumers about weight loss drugs and snacks.

A woman administers a GLP-1 subcutaneous injection into her stomach tissue for weight management, obesity, or diabetes care. Matt Fowler KC – stock.adobe.com “They still love the products they love,” he told Bloomberg in an article published Friday. “They’re just eating less of them.”

With nearly 30% of obese adults in the US expected to be on appetite-suppressing GLP-1 drugs by 2035, Tanner wants to know how the company can innovate.

He pointed to rival Mars as an example.

“Today’s consumer wants new products and Mars has been delivering,” Tanner told Bloomberg.

The biggest “Payday” for Hershey’s might come from its venture into protein powder.

It partnered with protein-powder company VitaKey on the project. Details remain scarce.

A mound of Hershey’s chocolate bars. Faina Gurevich – stock.adobe.com Since Tanner came to Hershey last year, he’s upped research and development spending by 25%, with the goal of pumping out “Good & Plenty” ideas, according to Bloomberg.

Hershey’s is also expanding its gum-and-mints division to accommodate consumers battling “Ozempic breath” – the bad-breath side effect of the pound-shedding drug. Bloomberg reported gum sales at the company went up 8% earlier this year. 

Hershey’s – which makes Skinny Pop, Dots Pretzels, and Pirate’s Booty – is looking to increase its savory offerings and is working on portion-controlled packaging. 

The protein snack bar market has been bursting at the wrapper — it’s expected to go from $21.94 billion to $32.66 billion by 2031, an 8.2% growth rate. Rxbar, the company behind the popular golden ticket-wrapped David bars, hit a $2.25 billion valuation this year, in the biggest deal of the year in the industry, according to Forbes. 

GLP-1s have posed challenges throughout the food business. Food giant Conagra has been scouring consumers’ credit-card data, social media posts and fast food orders to try to figure out what people still want to eat, according to the Wall Street Journal.

-

LOS ANGELES--(BUSINESS WIRE)--Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Caesars Entertainment, Inc. (“Caesars” or “the Company”) (NASDAQ: CZR) for potential breaches of fiduciary duty on the part of its directors and management.

INVESTIGATION DETAILS: The investigation focuses on determining if the Caesars board breached its fiduciary duties to shareholders. Tilman Fertitta has agreed to take Caesars private in a $5.7 billion all-cash deal paying $31 per share.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected]

WHY SBS? Schall, Brown & Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

More News From Schall, Brown & Schwartz LLP

Back to Newsroom

CoreWeave Stock Faces Fresh Pressure as Higher Rates Threaten AI Boom Summary

UBS lowered its CoreWeave price target to $105 from $120 but maintained its Buy rating, pointing to financing risks and weakening sentiment across AI stocks

CoreWeave CRWV shares dropped 2% in Friday morning trading as UBS cut its price target on the AI computing company to $105 from $120, while keeping its Buy recommendation.

The revised target reflects concerns about financing conditions and investor sentiment rather than a newly identified weakness in the company's operations. UBS analyst Karl Keirstead said demand trends, GPU pricing and CoreWeave's expansion into additional services remain supportive of its business outlook.

CoreWeave faces particular pressure when markets become less receptive to companies that need large amounts of capital. Building AI data centers requires substantial spending, while the company's negative free cash flow and reliance on debt make its valuation more sensitive to higher interest rates.

The stock's decline also comes amid broader uncertainty over how much companies will continue spending on artificial intelligence infrastructure. UBS views that wider reassessment as a key factor weighing on heavily funded AI businesses, rather than evidence that CoreWeave's own business prospects have suddenly weakened.

Although the bank retained its positive rating, the lower price target signals a more cautious view of the stock's near-term potential. Keirstead indicated that a recovery in investor confidence could take time as markets reassess AI investment and financing risks.

Disclosures I/we have no positions in any stocks mentioned, and have no plans to buy any new positions in the stocks mentioned within the next 72 hours.

Click for the complete disclosure

From a valuation perspective, Syntec Optics Holdings, Inc. (OPTX - Free Report) stock looks expensive. OPTX is currently trading at a trailing 12-month enterprise value/sales (EV/sales) of 8.77X, above the industry average of 2.78X. OPTX also trades at a higher valuation compared to other industry players, such as Duos Technologies Group, Inc. (DUOT - Free Report) and Bit Digital, Inc. (BTBT - Free Report) . Currently, DUOT and BTBT trade at EV/sales multiples of 2.42X and 2.21X, respectively. 

Image Source: Zacks Investment Research

While this elevated valuation reflects investor confidence in the company’s long-term potential, it also raises concerns about whether the stock can justify such lofty multiples. Considering the premium valuation, investors must be wondering whether they should buy, hold or sell the stock.

OPTX Stock’s Price PerformanceSyntec Optics shares have jumped 135.3% over the past year against the industry’s 28.7% decline. The Zacks Business Services sector has fallen 14.4% while the S&P 500 has advanced 13.2%. Meanwhile, OPTX has outperformed DUOS and BTBT, which declined 36.8% and 76.8%, in the same time frame.

Image Source: Zacks Investment Research

Business Tailwinds for OPTXSyntec Optics is benefiting from expanding demand for precision optics across U.S. defense platforms. In September 2026, the company reported more than $9 million in purchase orders, more than double its previously announced total. Demand spans missile-guidance optics, night-vision equipment, specialized targeting lasers and AI-enabled augmented-reality headsets. The breadth of applications and recurring orders could support production visibility as defense customers modernize their systems and deploy advanced optical technologies.

OPTX's space business is gaining traction through orders tied to national security and satellite communications. In September 2026, it secured an order for optics supporting U.S. Space Force infrastructure and reconnaissance satellites. The company is also ramping weekly shipments of precision waveguides for satellite antenna feeds. Management indicated that its space antenna portfolio could generate more than $1 million in annual revenues, while potential demand from expanding satellite constellations supports a longer-term opportunity.

Syntec Optics strengthened its lunar exploration exposure in October 2026 by announcing recurring production orders for precision components used in actuators on NASA's Artemis III rockets. These components help maintain engine positioning and flight trajectory. Management said the award increased its space technology backlog by 10%. The evolving mission plan, including orbital testing ahead of lunar operations, could provide additional production opportunities, although the timing and scale of future orders remain dependent on mission execution.

Syntec Optics is broadening its presence in AI infrastructure and advanced energy applications. In August 2026, it reported more than $4 million in orders linked to data center technologies and new fusion-energy orders valued at seven times those secured late in 2025. Its precision optics are designed for demanding fusion reactor environments, while micro-connectors and space-power systems expand the addressable product portfolio. Dedicating 5% of factory capacity to AI data center optics signals plans to build repeatable production in this market.

Improving financial flexibility could help Syntec Optics pursue its growing order pipeline. The company raised approximately $18.6 million in net proceeds through an April 2026 share offering and another $2.8 million from the underwriter's option exercise. It used roughly $6.8 million to repay debt and eliminated its bank credit line and related financial covenants. Sales increased to $14.8 million in the first half of 2026 from $13.6 million a year earlier, while operating cash flow improved to $0.2 million from $0.1 million.

Headwinds for OPTX’s BusinessSyntec Optics faces profitability pressures despite revenue growth. In the first half of 2026, gross profit declined to $3.1 million from $3.9 million a year earlier, as higher material costs, particularly aluminum, weighed on margins. The company reported a net loss of $0.6 million compared with nearly breakeven results a year ago. Customer concentration remains a concern, with three customers accounting for 52% of revenues. Competition from larger manufacturers, fluctuations in product mix and potential production disruptions could further pressure margins.

ConclusionOPTX’s growing defense and space orders, expanding AI infrastructure opportunities and improved financial flexibility support its long-term growth prospects. However, margin pressures, rising material costs, customer concentration and profitability challenges warrant caution.

Also, its valuation is higher than the industry average. For long-term investors, OPTX’s strong fundamentals may justify holding the stock, but investors looking to add the stock to their portfolios may want to wait for a better entry point. 

Apple’s first foldable iPhone is drawing praise for its sleek engineering and nearly invisible screen crease — but critics say its hefty design, camera compromises and uneven app support make the $1,999 gadget a tough sell for most consumers.

On top of that, early reports indicate the pricey device may be prone to crack.

The iPhone Duo hits stores Friday after drawing an 8.8 out of 10 from Engadget and 7 out of 10 from both The Verge and WIRED.

An image posted by a Reddit user shows a damaged iPhone Duo. reddit/Bitter_Offer7123
Engadget called Apple’s long-awaited entry into the foldable market “worth the wait,” while The Verge described it as a “messy, expensive, good time.”

Meanwhile, Wired called it an “astonishingly good first foldable.”

The device unfolds to reveal a 7.6-inch matte display that dramatically reduces glare, while its innovative hinge operates smoothly and holds the screen at different angles.

However, a handful of Reddit posts indicated severe disappointment for some buyers as of Friday afternoon.

“iPhone Duo screen cracked within 6 hours of ownership,” one user complained.

The person said they had taken out the device to show it off to a friend when they “felt something around the internal hinge, underneath the screen.”

“As I continued opening it, I heard an audible crack, and the screen broke right along the hinge,” the post continued. “There were no marks or damage on the inner screen’s surface or the external hinge to suggest anything had been caught or damaged.”

The person zoomed back to an Apple store, where staff gave the customer a new Duo.

Another Reddit user posted a video of a cracked device, commenting: “Looks like some of them are cracking in the exact same area.”

Yet another image of a cracked Duo had the caption, “I’ve seen several iPhone Duos with damage in this exact same spot.”

A display of iPhone Duo smartphones is seen during a launch in Manhattan on Friday. Anadolu via Getty Images
Still, reviewers sung praises of the device’s titanium construction and smooth folding mechanism.

The crease hasn’t disappeared entirely, however. Several critics noted that it remains visible at certain angles and can still be felt when running a finger across the screen.

Apple’s anti-reflective finish also comes with a trade-off: Colors can appear less vibrant and blacks less deep than on the company’s non-folding premium iPhones.

At 254 grams and 11.3 millimeters thick when folded, the Duo’s bulk emerged as one of the most frequent complaints.

Its relatively small 5.4-inch outer display also drew mixed reactions, with some reviewers praising its compact footprint and others complaining that websites and apps feel cramped on the device.

The Wall Street Journal delivered one of the harshest assessments, describing the device as “Too Much iPhone, Too Little iPad.”

A display of iPhone Duo smartphones is seen during the launch in Manhattan on Friday. Anadolu via Getty Images
Despite its expansive inner display, the Duo falls short of an iPad when it comes to productivity, with more limited multitasking and keyboard capabilities, according to the Journal.

Software emerged as another major sticking point.

While Apple’s own apps generally make a seamless transition between the folded and unfolded screens, reviewers found that many third-party offerings weren’t properly optimized for the device.

Wired’s Julian Chokkattu described the problem: “Thick, black bars on the sides, with a phone-sized app in the middle of this tablet-like display.”

Engadget’s Sam Rutherford called the gap between optimized and unoptimized apps “the biggest growing pain you’ll face on Apple’s first foldable.”

Even the Duo’s multitasking capabilities have limitations.

Users can run two apps side by side, but Apple’s software restricts them to a fixed 50-50 split, without the freedom to open a third floating window.

Suraya Shivji, 28, a New York resident visiting San Francisco for a friend’s wedding, reacts to seeing the iPhone Duo in action at the Apple Union Square store in San Francisco on Friday. REUTERS
“If you have two apps split-screen on the Duo, Apple won’t let you resize one app to be slightly bigger than the other like you can on Android,” Chokkattu wrote in Wired.

“Here, a 50-50 split is always enforced. You can’t add a floating third app when in split-screen either, even though Apple has offered a similar capability on iPads for years.”

Those complaints could ease as developers adapt their apps to the new format.

Wired reported that several popular apps received updates during the device’s testing period, while Creative Strategies said the share of its installed apps optimized for the Duo increased dramatically over roughly six days.

Other shortcomings won’t be fixed with software updates.

“Despite being Apple’s most expensive iPhone, the iPhone Duo does not have its most powerful camera system,” Chance Miller of 9to5Mac wrote.

Its main and ultrawide cameras generally earned favorable marks, but several reviewers found their performance inferior to the iPhone 18 Pro, particularly in low light.

The hidden 4-megapixel camera beneath the inner display also disappointed, with Gizmodo reporting washed-out image quality.

An image provided by a Reddit user shows iPhone Duo models with damage in the exact same spot. reddit/robnaught
“I hear you: it feels absurd that a $2,000 phone—the most expensive iPhone ever—does not have the most versatile camera system that Apple has to offer,” Gizmodo’s Raymond Wong wrote, adding that he “noticed more lens flares coming off streetlights and more smeared details.”

Still, the folding design offers some novel photographic advantages, including the ability to use the higher-quality rear cameras for selfies while viewing the shot on the outer screen.

Battery life, meanwhile, exceeded the expectations of several reviewers, even if it couldn’t match Apple’s top conventional iPhone.

Tom’s Guide found that the Duo lasted 13 hours and 20 minutes in a continuous 5G web-browsing test using its larger display.

That handily beat the 10 hours and six minutes recorded by Samsung’s Galaxy Z Fold 8, but fell well short of the iPhone 18 Pro Max’s 17 hours and 31 minutes.

Other reviewers reported getting through a typical day without needing to recharge, although intensive use of the larger screen could drain the battery considerably faster.

The divergent ratings reflected less disagreement over the Duo’s strengths and weaknesses than differing views about whether its folding design justifies the compromises.

Tom’s Guide called it the “best designed foldable yet,” while 9to5Mac concluded that a conventional iPhone remains the more practical choice for most consumers.

The Post has sought comment from Apple.